New
HealthMore in Health→
Engineered TIL Therapy Shows Early Safety Signal in Resistant Melanoma
Key Takeaways
- The pooled analysis included 37 patients with checkpoint inhibitor-resistant advanced melanoma.
- No dose-limiting toxicities, ICU care or treatment-related deaths were reported.
- An early adverse event prompted dose reductions and protocol modifications.
- The supplied report does not provide response-rate figures.
DE
DT Editorial Team··via nature.com